News · 26 weeks87+200%
2026-04-192026-10-11
Mix3690d
- Insider23(64%)
- Other5(14%)
- SEC Filings3(8%)
- Earnings2(6%)
- Leadership2(6%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 3 filed by Danaher Corporation3 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 3 filed by Danaher Corporation3 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Danaher Corporation4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Danaher Corporation4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- PRDanaher Collaborates with NVIDIA to Advance Autonomous ScienceCollaboration will bring together NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and dataWASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) today announced a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of scientific discovery. As part of Danaher's broader effort to shape the future of AI-enabled science, the companies are working to combine Danaher's scientific instrumentation, automation technologies, laboratory workflow software and domain expertise with NVIDIA accelerated computing and AI technologies. The goal is to help researchers move faster from prediction to experimental evidence, creat
- SECSEC Form 8-K filed by Danaher Corporation8-K - DANAHER CORP /DE/ (0000313616) (Filer)
- PRDanaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of DirectorsWASHINGTON, Oct. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or "the Company") today announced the appointment of Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to the Danaher Board of Directors on October 9, 2026. Dr. Hershberg has also been appointed to the Company's Science and Technology Committee. Alan G. Spoon will not stand for reelection at Danaher's 2027 Annual Meeting of Shareholders, retiring from the Board of Directors at that time.Danaher has expanded the size of its Board from 11 to 13 directors to accommodate these appointments. Danaher's Nominating & Governance Committee also continues to evaluate Board composition as part of its regular governance
- PRDanaher Accelerates Life Sciences Research with New AI-powered Autonomous LabHelping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher's ecosystem of industry-leading technologiesWASHINGTON, Oct. 7, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) today announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently. Expected to operate at scale in early 2027, the lab will combine artificial intelligence, robotics and technologies from several Danaher operating companies in one connected workflow. It is the first step in a broader Danaher initiative to create smart instruments, i
- INSIDERNew insider Moler Heathre T claimed ownership of 5,356 shares (SEC Form 3)3 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERNew insider Muppaneni Shashanka claimed ownership of 5,901 shares (SEC Form 3)3 - DANAHER CORP /DE/ (0000313616) (Issuer)
- PRJulie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive OfficerWASHINGTON, Oct. 1, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or "the Company") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Chief Executive Officer and has joined Danaher's Board of Directors, as previously announced on August 3, 2026. Since joining the Company in 2017, Ms. Sawyer Montgomery has held roles of increasing responsibility spanning commercial operations, R&D, and business leadership. In those roles, she has built a track record of advancing innovation and commercial excellence and accelerating share gain. She has also contributed to optimizing the Danaher Business System to strengthen operating performance.A
- PRDanaher Schedules Third Quarter 2026 Earnings Conference CallWASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.Yo
- PRIntegrated DNA Technologies and Aldevron Launch New Cas9 mRNA Solutions to Accelerate Path from Gene Editing Research to DevelopmentCo-developed offering connects Integrated DNA Technologies’ CRISPR engineering and analysis expertise with Aldevron’s mRNA manufacturing capabilities, helping customers move from discovery toward clinical development with greater speed, continuity, and confidence.Research grade S.p. Cas9 mRNA is available in wild type and SpyFi™ high-fidelity formats to support CRISPR-based research applications.Optimized mRNA constructs are designed for high on-target editing, reduced off-target activity with SpyFi, low toxicity, and delivery method flexibility.Danaher companies Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a premier manufacturing partner for DNA, RNA, and pr
- PRDanaher Announces Quarterly DividendWASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend
- ANALYSTUBS resumed coverage on Danaher with a new price targetUBS resumed coverage of Danaher with a rating of Buy and set a new price target of $250.00
- INSIDERPresident & CEO Blair Rainer sold $12,736,095 worth of shares (58,255 units at $218.63) (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERExecutive Vice President Riley Christopher Paul was granted 41,072 shares, increasing direct ownership by 201% to 61,472 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Financial Officer Gugino Matthew E4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by SVP-Chief Legal Officer Leiken Jonathan4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSVP, Chief Science Officer Gutierrez-Ramos Jose-Carlos was granted 13,477 shares, increasing direct ownership by 71% to 32,495 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Sawyer Montgomery Julie A4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by VP, Chief Accounting Officer Bouda Christopher4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERExecutive Vice President Milosevich Gregory M was granted 15,402 shares, increasing direct ownership by 170% to 24,467 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERChairman of Exec. Committee Rales Mitchell P was granted 500,000 shares, increasing direct ownership by 939% to 553,228 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERChairman Rales Steven M was granted 500,000 shares, increasing direct ownership by 16% to 3,605,808 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
DHR FAQ
7 questionsWhat does Danaher Corporation do?
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and...Where does DHR stock trade?
Danaher Corporation (DHR) is listed on NYSE.What sector and industry is DHR in?
Danaher Corporation operates in the Industrials sector, Industrial Machinery/Components industry.Does DHR pay a dividend?
DHR's most recent ex-dividend date was 2026-09-30 with a cash dividend of $0.40 per share. No future ex-date is on file yet.What are analysts saying about DHR?
Danaher Corporation has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-09-09.What companies are similar to DHR?
Notable peers in the same industry include ASML (ASML Holding N.V. New York Registry Shares), LRCX (Lam Research Corporation), TMO (Thermo Fisher Scientific Inc), DE (Deere & Company), ETN (Eaton Corporation PLC). Compare DHR side-by-side with any of them on Quantisnow.How can I track DHR on Quantisnow?
Quantisnow aggregates Danaher Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DHR to receive live email and push alerts on every new disclosure.